Grant✓ Small businesses may apply
Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
National Institutes of Health
- Opportunity #
- PAR-25-103
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.399
- Status
- posted
- Posted
- Nov 5, 2024
- Closes
- Oct 25, 2027
- Funding instrument
- Cooperative Agreement
- Category
- Education, Health
- Cost sharing required
- No
Who can apply
- •Small businesses
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •County governments
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •Independent school districts
- •City or township governments
- •Special district governments
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •For profit organizations other than small businesses
- •Public and State controlled institutions of higher education
- •State governments
- •Public housing authorities/Indian housing authorities
- •Native American tribal governments (Federally recognized)
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •Private institutions of higher education
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Synopsis
The purpose of this NOFO is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.
Contact
National Institutes of Health · grantsinfo@nih.gov